Top Markets
#1 Derive Derive +33.13%
#2 Cross Cross +16.48%
#3 Geodnet Geodnet +10.63%
#4 Gama Token Gama Token +9.17%
#5 The Bitcoin Bull The Bitcoin Bull +8.05%
#6 Steakhouse ETH Morpho Vault Steakhouse ETH Morpho Vault +7.25%
#7 Quantum Resistant Ledger Quantum Resistant Ledger +6.82%
#8 Cap Cap +6.78%
#9 Humanity Humanity +6.62%
#10 Starpower Starpower +5.78%
Coin of the day
Derive Derive
Settings
Language
ENGLISH
Currency
USD
Theme
Creative Medical Technology Holdings, Inc. Creative Medical Technology Holdings, Inc.

Creative Medical Technology Holdings, Inc.

CELZ
Rank in Stocks #35972
Creative Medical Technology Holdings, Inc., a biotechnology firm based in... Creative Medical Technology Holdings, Inc., a biotechnology firm based in Phoenix, Arizona, specializes in advancing adult stem cell treatments. The company's core focus spans several medical fields, including immunology, urology, orthopedics, and neurology. Among its therapeutic offerings are CaverStem, designed to address erectile dysfunction; FemCelz, which aims to restore genital sensitivity and alleviate dryness; StemSpine, developed to treat chronic lower back pain; ImmCelz, intended for stroke patients; and OvaStem, a solution for female infertility.
Share Price
$1.25
Last synced: 2026-08-14
Market Cap
$3.21M
Change (1 day)
0.40%
Change (1 year)
-60.10%
Country
US
Trade Creative Medical Technology Holdings, Inc. (CELZ)

Category

Healthcare
P/E ratio for Creative Medical Technology Holdings, Inc. (CELZ)
P/E ratio as of 2026 TTM: 0
According to Creative Medical Technology Holdings, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Creative Medical Technology Holdings, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 18.38 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.